Seebri Neohaler (Glycopyrrolate) for COPD | MyCOPDTeam

Connect with others who understand.

sign up Log in
About MyCOPDTeam
Powered By

Seebri Neohaler is a prescription drug approved by the Food and Drug Administration (FDA) for long-term maintenance of airway obstruction in people with chronic obstructive pulmonary disease (COPD). Seebri Neohaler is also known by its drug name, Glycopyrrolate.

Seebri Neohaler is an anticholinergic and a bronchodilator, a drug that dilates the bronchi and bronchioles in the lungs, making it easier to breathe. Seebri Neohaler is believed to work by relaxing smooth muscles in the airways. Seebri Neohaler is considered a long-acting bronchodilator.

How do I take it?
Seebri Neohaler is inhaled orally twice a day.

Seebri Neohaler comes in the form of powder capsules to be taken using the special Neohaler inhaler.

Side effects
The FDA-approved label for Seebri Neohaler lists common side effects including cold symptoms and upper respiratory tract infections.

Rare but serious side effects listed for Seebri Neohaler include paradoxical bronchospasm (bronchospasm that happens after using medication) and worsening of glaucoma and urinary retention.

For more details about this treatment, visit:

Seebri Neohaler highlights of prescribing information (PDF) – Novartis

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in